Novel Technologies News for November 2022

Novel Technologies News Archive

Lab Innovations celebrates its ten year anniversary in style Lab Innovations celebrates its ten year anniversary in style

98 per cent of exhibitors sign up for Lab Innovations 2023 after a record breaking event this year

IBM and Algorithmiq join forces to pave the way toward useful quantum advantage for quantum chemistry IBM and Algorithmiq join forces to pave the way toward useful quantum advantage for quantum chemistry

Collaboration with innovative Finnish software company to explore how to reduce the time and cost of drug discovery and development using quantum computers

Publication in Nature Chemistry Demonstrates the Benefits of Native Mass Spectrometry in the Interrogation of Target Ecosystems and Drug Discovery Publication in Nature Chemistry Demonstrates the Benefits of Native Mass Spectrometry in the Interrogation of Target Ecosystems and Drug Discovery

Joint publication in Nature Chemistry between OMass Therapeutics’ scientists and co-founder Professor Dame Carol Robinson’s team at Oxford University. Data demonstrates the ability of native mass spectrometry (MS) to interrogate the pharmacology of the beta-1 adrenergic receptor (ß1AR), a G protein-coupled receptor (GPCR). Discovery of endogenous zinc ion as a positive allosteric modulator in well studied receptor exemplifies the potential of native MS to uncover novel insights that may be important for drug discovery

International research coalition verifies safe surgical access to the central core of the human cochlea for the very first time International research coalition verifies safe surgical access to the central core of the human cochlea for the very first time

A team of surgeons and scientists from the UK, Sweden and Canada, funded by Rinri Therapeutics, has confirmed secure surgical access to the central core of the human cochlea The research, published in Scientific Reports, is critical to the first in-human trials of new cell, gene and drug therapies for the inner ear, and will assist with treatment for improving hearing loss and deafness over the long-term

Enhanced pacemaker developer Ceryx Medical wins prestigious Institute of Physics award Enhanced pacemaker developer Ceryx Medical wins prestigious Institute of Physics award

University of Bath spin-out hailed for revolutionary development to provide world’s first curative therapy for heart failure

Patient-specific cancer tumours replicated in 3D bioprinting advance Patient-specific cancer tumours replicated in 3D bioprinting advance

Bowel cancer patients could in future benefit from a new 3D bioprinting technology which would use their own cells to replicate the complex cellular environment of solid tumours in 3D models. The University of Bristol-led advance, published in Biofabrication, would allow clinicians to treat the models, known as spheroids, with chemotherapy drugs and radiation to help them understand an individual patient’s resistance to therapies.

ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research

BOSTON, Mass. and Oxford, UK – November 2, 2022 – ROME Therapeutics and Enara Bio, two leading biotechnology companies focused on developing novel medicines driven by insights to the dark genome, today announced that they will host the inaugural Dark Genome Symposium on Monday, November 7, 2022 at ROME’s headquarters in Boston. This one-day event brings together leaders from academia, biotech and pharma working on the dark genome to share knowledge, opportunities, applications and challenges to solve as a community.